Apaxen is a privately-held biotechnology company developing innovative treatments for patients with diseases that depend on chronically enhanced MIF expression.

We develop first-in-class small molecule inhibitors and degraders of MIF, a key driver of inflammation and fibrosis in many diseases. Our drugs work by blocking the intra and extracellular biological activity of Macrophage Migration Inhibitory Factor (MIF). Our First-In-Class approach is based on more than 30 years of MIF research.. 

Apaxen’s lead compound, MFC-1040 has the potential te become an effective treatment for many inflammatory and fibrotic diseases. With the growing understanding of the importance of MIF for the progression of inflammatory diseases, the list of diseases that could be successfully treated with MFC-1040 is rapidly becoming longer.

Apaxen intents to use its platform for discovery and development of MIF inhibitors and MIF protein degrading agents for treatment of inflammatory and fibrotic diseases for which currently no effective treatments exist.